PFE Dec 2022 55.000 call
| Previous close | 0.0400 |
| Open | 0.0400 |
| Bid | 0.0200 |
| Ask | 0.0300 |
| Strike | 55.00 |
| Expiry date | 2022-12-16 |
| Day's range | 0.0200 - 0.0400 |
| Contract range | N/A |
| Volume | |
| Open interest | 14.65k |
- Zacks
Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants
Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.
- Zacks
Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab
Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.
- Business Wire
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease
NEW YORK & CAMBRIDGE, Mass., December 06, 2022--Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19. PLpro is an essential enzyme, which, along with the main protease (Mpro), plays an important role in viral replication. This program will expand Pfizer’s innovative anti-infective p
